Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations
This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. Th...
Saved in:
Other Authors: | , , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_80940 | ||
005 | 20220506 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220506s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-3642-2 | ||
020 | |a 9783036536415 | ||
020 | |a 9783036536422 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-3642-2 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a MMG |2 bicssc | |
100 | 1 | |a Ruaro, Barbara |4 edt | |
700 | 1 | |a Salton, Francesco |4 edt | |
700 | 1 | |a Confalonieri, Paola |4 edt | |
700 | 1 | |a Ruaro, Barbara |4 oth | |
700 | 1 | |a Salton, Francesco |4 oth | |
700 | 1 | |a Confalonieri, Paola |4 oth | |
245 | 1 | 0 | |a Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (178 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. The present Special Issue aims to provide an overview of the complexity of vascular and pulmonary manifestations of rheumatologic diseases and helps in knowledge to manage them. The eleven published articles here collected underline the complexity of rheumatic diseases and the difficult to treated them. The manuscripts provide an overview of the pathophysiology and current treatment regimes of these disorders, highlighting tools which assist with diagnosis, risk stratification and therapy. Finally, we underline the importance of a multidisciplinary team working using the skills of clinicians, radiologists, and pathologists. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
650 | 7 | |a Pharmacology |2 bicssc | |
653 | |a systemic sclerosis | ||
653 | |a scleroderma | ||
653 | |a interstitial lung disease | ||
653 | |a pulmonary function tests | ||
653 | |a high-resolution computed tomography | ||
653 | |a rheumatic | ||
653 | |a pulmonary arterial hypertension | ||
653 | |a targeted therapy | ||
653 | |a systemic lupus erythematosus | ||
653 | |a airway disease | ||
653 | |a shrinking lung syndrome | ||
653 | |a diffuse alveolar hemorrhage | ||
653 | |a pleurisy | ||
653 | |a infection | ||
653 | |a cardiopulmonary exercise testing | ||
653 | |a osteopontin | ||
653 | |a connective tissue diseases | ||
653 | |a pulmonary involvement | ||
653 | |a microvascular involvement | ||
653 | |a nailfold capillaroscopy | ||
653 | |a rheumatoid arthritis | ||
653 | |a interstitial lung diseases | ||
653 | |a CX3CL1/fractalkine | ||
653 | |a CX3CR1 | ||
653 | |a M1 macrophage | ||
653 | |a M2 macrophage | ||
653 | |a SKG mice | ||
653 | |a heart failure | ||
653 | |a 3D-echocardiography | ||
653 | |a ventricular function | ||
653 | |a outcome | ||
653 | |a ventricular-arterial coupling | ||
653 | |a antifibrotic agents | ||
653 | |a COVID-19 | ||
653 | |a IPF | ||
653 | |a progressive fibrosing ILD | ||
653 | |a UIP | ||
653 | |a pharmacological interactions | ||
653 | |a fibromyalgia | ||
653 | |a gastrointestinal symptoms | ||
653 | |a probiotic | ||
653 | |a VSL#3® | ||
653 | |a efficacy | ||
653 | |a tolerability | ||
653 | |a polymyalgia rheumatica | ||
653 | |a vagus nerve stimulation | ||
653 | |a inflammatory response | ||
653 | |a PMR | ||
653 | |a t-vns | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5278 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/80940 |7 0 |z DOAB: description of the publication |